C16orf74 is a novel prognostic biomarker and associates with immune infiltration in head and neck squamous cell carcinoma
PLoS ONE,
Год журнала:
2025,
Номер
20(5), С. e0322701 - e0322701
Опубликована: Май 7, 2025
Head
and
neck
squamous
cell
carcinoma
(HNSC)
is
a
prevalent
aggressive
malignancy
with
poor
prognosis,
underscoring
the
need
for
novel
biomarkers
therapeutic
strategies.
This
study
investigates
role
of
C16orf74
as
potential
diagnostic
prognostic
biomarker
in
HNSC.
Bioinformatics
analyses
revealed
that
significantly
overexpressed
HNSC
associated
advanced
disease
stages,
therapy
resistance,
shorter
overall
progression-free
survival.
A
nomogram
integrating
expression
clinicopathological
features
demonstrated
robust
predictive
performance.
Functional
enrichment
immune
infiltration
suggest
high
might
contribute
to
an
immunosuppressive
tumor
microenvironment
by
reducing
key
populations,
such
B
cells,
T
natural
killer
which
are
critical
anti-tumor
immunity.
Moreover,
was
inversely
checkpoint
immunotherapy
response,
highlighting
its
blockade
(ICB)
efficacy.
Drug
sensitivity
identified
agents,
including
arsenic
trioxide,
carmustine,
vincristine,
quercetin,
carboplatin
patients
expression.
These
findings
highlight
target
improve
management.
Язык: Английский
Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers
Journal for ImmunoTherapy of Cancer,
Год журнала:
2025,
Номер
13(5), С. e011140 - e011140
Опубликована: Май 1, 2025
Background
Durvalumab
(D;
anti-programmed
cell
death
ligand
1
(PD-L1))
monotherapy
or
in
combination
with
tremelimumab
(T;
anti-cytotoxic
T
lymphocyte
antigen-4
(CTLA-4))
have
demonstrated
efficacy
advanced
cancers.
However,
higher
incidences
of
adverse
events
(AEs)
and
immune-mediated
AEs
(imAEs)
were
observed
D+T
compared
D
clinical
trials.
While
safety
data
been
published
from
individual
trials
without
T,
we
report
a
comprehensive
analysis
broad
population
across
multiple
tumor
types.
Methods
A
retrospective
was
conducted
using
pooled
phase
I
to
III
patients
non-small
lung
cancer
(NSCLC),
recurrent
metastatic
squamous
carcinoma
the
head
neck,
unresectable
hepatocellular
(uHCC),
gastric
adenocarcinoma,
urothelial
carcinoma,
who
received
either
(N=4,045;
13
trials)
(N=3,319;
14
trials).
Results
Compared
monotherapy,
treated
had
maximum
grade
3
4
(49.5%
vs
39.6%),
treatment-related
(22.1%
11.5%),
any
imAE
(30.2%
17.4%),
imAEs
(11.0%
4.3%).
The
majority
non-serious,
low
manageable
both
datasets.
Higher
mainly
driven
by
diarrhea/colitis
(7.6%
1.9%)
dermatitis/rash
(4.7%
1.6%).
Fatal
infrequent
similar
between
(0.4%
0.3%).
Across
types,
hypothyroid
most
frequently
reported
(D+T:
9.7%;
monotherapy:
7.6%).
As
expected,
given
organ
involvement,
pneumonitis
NSCLC
5.4%;
4.7%),
while
hepatic
uHCC
7.9%;
6.1%).
Conclusions
types;
however,
fatal
ImAEs
dataset
consistent
profiles
agents
dual
PD-(L)1
CTLA-4
inhibition.
Overall,
tolerable
Язык: Английский
Preclinical in vitro models of HNSCC and their role in drug discovery - an emphasis on the cancer microenvironment and microbiota
Expert Opinion on Drug Discovery,
Год журнала:
2024,
Номер
unknown, С. 1 - 21
Опубликована: Дек. 15, 2024
Head
and
neck
squamous
cell
carcinoma
(HNSCC)
is
the
seventh
most
common
cancer
worldwide.
Treatment
options
patient
outcomes
have
not
improved
significantly
over
past
decades,
increasing
need
for
better
preclinical
models.
Holistic
approaches
that
include
an
intact
functional
immune
compartment
along
with
patient's
individual
tumor
microbiome
will
help
improve
predictive
value
of
novel
drug
efficacy.
Язык: Английский